[Evaluation of the value of triple diagnosis in prenatal medicine].
The evaluation for every new method of early diagnostics is the criterion of quality of previous methods. The Triple diagnostics in the prenatal medicine however does not fulfill the criterion of standard for example for early diagnostics in gynecological oncology. Particularly, the precision in laboratories cannot be safely assumed so that false positive as well as false negative results are possible. The consequences of this method of early diagnostics are uncertainty for patients and physicians and of high expenditure for both.
Krebs
D
D
Universitäts-Frauenklinik Bonn.
D000649:Amniocentesis / Q000191:economics; D006063:Chorionic Gonadotropin / Q000097:blood*; D003362:Cost-Benefit Analysis; D003430:Cross-Sectional Studies; D004314:Down Syndrome / Q000191:economics / Q000453:epidemiology / Q000517:prevention & control*; D004964:Estriol / Q000652:urine*; D005069:Evaluation Studies as Topic; D005260:Female; D005858:Germany; D005865:Gestational Age; D006801:Humans; D015994:Incidence; D007231:Infant, Newborn; D008423:Maternal Age; D011237:Predictive Value of Tests; D011247:Pregnancy; D011296:Prenatal Diagnosis / Q000191:economics*; D011785:Quality Assurance, Health Care / Q000191:economics; D012016:Reference Values; D000509:alpha-Fetoproteins / Q000378:metabolism*
D006063:Chorionic Gonadotropin; D000509:alpha-Fetoproteins; D004964:Estriol